Browse hierarchy: [Clinical Chemistry (CH)](/submissions/CH) → [Subpart B — Clinical Chemistry Test Systems](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems) → [21 CFR 862.1357](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/862.1357) → SBA — Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate

# SBA · Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate

_Clinical Chemistry · 21 CFR 862.1357 · Class 2_

**Canonical URL:** https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/SBA

## Overview

- **Product Code:** SBA
- **Device Name:** Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate
- **Regulation:** [21 CFR 862.1357](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/862.1357)
- **Device Class:** 2
- **Review Panel:** [Clinical Chemistry](/submissions/CH)
- **Implant:** yes

## Identification

The Eversense AP CGM System is a continuous glucose monitoring system (CGM) that provides glucose measurements every 5 minutes over a 40-400 mg/dL range. It consists of a glucose sensor (the Eversense AP Sensor) containing dexamethasone acetate, which is inserted under the skin; an externally worn Eversense AP Smart Transmitter; and the Eversense Mobile Medical Application (MMA). The system is indicated for continually measuring glucose levels for up to 6 months in people (18 years and older) with diabetes, to replace fingerstick blood glucose measurements for treatment decisions, and to autonomously communicate with digitally connected devices, including automated insulin dosing (AID) systems.

## Classification Rationale

Class II (special controls). The device is an integrated continuous glucose monitoring system (iCGM) with a sensor containing dexamethasone acetate, classified under 21 CFR 862.1357.

## Special Controls

Dexamethasone acetate-eluting integrated continuous glucose monitoring systems must comply with the following special controls:

## Recent Cleared Devices (2 of 2)

| Record | Device Name | Applicant | Decision Date | Decision |
| --- | --- | --- | --- | --- |
| [K241335](https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/SBA/K241335.md) | Eversense 365 Continuous Glucose Monitoring (CGM) System | Senseonics, Incorporated | Sep 16, 2024 | SESE |
| [DEN230052](https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/SBA/DEN230052.md) | Eversense AP CGM System | Senseonics, Incorporated | Apr 29, 2024 | DENG |

## Top Applicants

- Senseonics, Incorporated — 2 clearances

---

**Source:** [https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/SBA](https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/SBA)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com